# Fortress Biotech, Inc.: Form 10-K/A for the period ended Dec 31, 2020

- Company: [Fortress Biotech, Inc.](/companies/fbio.md) (CIK 1429260)
- Form: 10-K/A
- Filed: 2021-04-09
- Accepted by EDGAR: Apr 9, 2021, 17:29 ET
- Period: 2020-12-31
- Accession: 0001558370-21-004130
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1429260/000155837021004130/fbio-20201231x10ka.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1429260/000155837021004130/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2020-01-01 to 2020-12-31 | $45.6m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2020-01-01 to 2020-12-31 | $14.6m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months, 2020-01-01 to 2020-12-31 | $64.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2020-01-01 to 2020-12-31 | $61.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2020-01-01 to 2020-12-31 | −$94.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2020-01-01 to 2020-12-31 | $136.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2020-01-01 to 2020-12-31 | −$46.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2020-01-01 to 2020-12-31 | −$0.65 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months, 2020-01-01 to 2020-12-31 | −$83.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2020-01-01 to 2020-12-31 | $1.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2020-01-01 to 2020-12-31 | $237.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months, 2020-01-01 to 2020-12-31 | $70.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2020-12-31 | $233.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-12-31 | $261.6m | us-gaap:AssetsCurrent |
| Total assets | at 2020-12-31 | $328.8m | us-gaap:Assets |
| Current liabilities | at 2020-12-31 | $48.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-12-31 | $131.8m | us-gaap:Liabilities |
| Long-term debt | at 2020-12-31 | $51.7m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2020-12-31 | $100.3m | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1429260/000155837021004130/fbio-20201231x10ka.htm

Filed Apr 9, 2021.
Source: SEC EDGAR, the filing index for accession 0001558370-21-004130. Last ingested by Listed: Nov 14, 2026, 11:27 ET. No prices; not investment advice.
